Stocks
GlaxoSmithKline (GSK) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 26.3% | 29.3% | 29.9% | 21.3% | 31.8% | 34.4% | ||
| Changes by years, y/y, % | -7pp | +3pp | +1pp | -9pp | +11pp | -0.8% | |||
GlaxoSmithKline. EBITDA margin, %
GlaxoSmithKline. EBITDA margin, changes, pp
GlaxoSmithKline (GSK) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | 40.4% | 39.3% | 22.1% | 22.1% | 36.4% | 34.4% | |
| Changes by years, y/y, % | +11pp | +25pp | +8pp | +8pp | -5pp | |||
| Changes by quarters, q/q, % | -1pp | -1pp | -17pp | 0pp | +14pp | |||
